#2 - Editas Medicine (NASDAQ:EDIT)
The next company on this list of gene therapy stock is Editas Medicine (NASDAQ: EDIT). The company is working on its own gene editing platform based on CRISPR technology. This is where things can get a little confusing. Many companies will use CRISPR technology, but they are not affiliated with CRSPR Therapeutics or its gene editing platform.
That’s the case with Editas which has its own pipeline of candidates that is based on CRISPR technology. And the company has its own partnerships in particular with Allergan (NYSE: AGN).
EDIT stock currently has a consensus rating of Hold from the analysts surveyed by MarketBeat. One reason for that may be the level of short interest in the small-cap stock which is more than 30% as of this writing. This isn’t unusual for companies in this space, especially before they have a therapy approved.
About Editas Medicine
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Read More - Current Price
- $2.37
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $9.08 (283.3% Upside)
